Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Bilateral Macular Choroidal Infarction as a Manifestation of Giant Cell Arteritis.

Ness SD, Butler NJ, Poulaki V.

Ophthalmic Surg Lasers Imaging Retina. 2018 Jul 1;49(7):540-543. doi: 10.3928/23258160-20180628-12.

PMID:
30021043
2.

Lens regeneration in children.

Vavvas DG, Dryja TP, Wilson ME, Olsen TW, Shah A, Jurkunas U, Pineda R, Poulaki V, Palioura S, Veldman P, Moreno-Montañés J, Pinazo-Duran MD, Pastor JC, Tsilimbaris M, Rhee D, Colby K, Hunter DG, Thanos S, Sakamoto T, Pasquale LR, Miller JW, VanderVeen D, Lambert SR.

Nature. 2018 Apr 4;556(7699):E2-E3. doi: 10.1038/nature26149. No abstract available.

PMID:
29620729
3.

ICG-001 Exerts Potent Anticancer Activity Against Uveal Melanoma Cells.

Kaochar S, Dong J, Torres M, Rajapakshe K, Nikolos F, Davis CM, Ehli EA, Coarfa C, Mitsiades N, Poulaki V.

Invest Ophthalmol Vis Sci. 2018 Jan 1;59(1):132-143. doi: 10.1167/iovs.17-22454.

4.

Teleretinal imaging for detection of referable macular degeneration.

Duchin KS, Asefzadeh B, Poulaki V, Rett D, Marescalchi P, Cavallerano A.

Optom Vis Sci. 2015 Jun;92(6):714-8. doi: 10.1097/OPX.0000000000000598.

PMID:
25955641
5.

Management of submacular hemorrhage.

Malik FF, Poulaki V.

Int Ophthalmol Clin. 2014 Spring;54(2):51-9. doi: 10.1097/IIO.0000000000000018. Review. No abstract available.

PMID:
24613884
6.

Protein kinase C inhibitors sensitize GNAQ mutant uveal melanoma cells to ionizing radiation.

Cerne JZ, Hartig SM, Hamilton MP, Chew SA, Mitsiades N, Poulaki V, McGuire SE.

Invest Ophthalmol Vis Sci. 2014 Apr 7;55(4):2130-9. doi: 10.1167/iovs.13-13468.

7.

Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy.

Mitsiades N, Chew SA, He B, Riechardt AI, Karadedou T, Kotoula V, Poulaki V.

Invest Ophthalmol Vis Sci. 2011 Sep 14;52(10):7248-55. doi: 10.1167/iovs.11-7398.

8.

Angiogenesis assays.

Poulaki V.

Methods Mol Biol. 2011;731:345-58. doi: 10.1007/978-1-61779-080-5_28.

PMID:
21516420
9.

TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations.

Joussen AM, Doehmen S, Le ML, Koizumi K, Radetzky S, Krohne TU, Poulaki V, Semkova I, Kociok N.

Mol Vis. 2009 Jul 25;15:1418-28.

10.

Role of alpha 4 integrin (CD49d) in the pathogenesis of diabetic retinopathy.

Iliaki E, Poulaki V, Mitsiades N, Mitsiades CS, Miller JW, Gragoudas ES.

Invest Ophthalmol Vis Sci. 2009 Oct;50(10):4898-904. doi: 10.1167/iovs.08-2013. Epub 2009 Jun 24.

PMID:
19553613
11.

Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.

Poulaki V, Mitsiades CS, Kotoula V, Negri J, McMullan C, Miller JW, Marks PA, Mitsiades N.

Invest Ophthalmol Vis Sci. 2009 Sep;50(9):4072-9. doi: 10.1167/iovs.09-3517. Epub 2009 Apr 22.

PMID:
19387079
12.

Retinoblastoma: genetics and pathology.

Poulaki V, Mukai S.

Int Ophthalmol Clin. 2009 Winter;49(1):155-64. doi: 10.1097/IIO.0b013e3181924bc2. Review. No abstract available.

PMID:
19125074
13.

Genetics of anterior and stromal corneal dystrophies.

Poulaki V, Colby K.

Semin Ophthalmol. 2008 Jan-Feb;23(1):9-17. doi: 10.1080/08820530701745173. Review.

PMID:
18214787
14.

The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.

Poulaki V, Mitsiades CS, Kotoula V, Negri J, McMillin D, Miller JW, Mitsiades N.

Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4706-19.

PMID:
17898295
15.

Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition.

Mitsiades CS, Hayden P, Kotoula V, McMillin DW, McMullan C, Negri J, Delmore JE, Poulaki V, Mitsiades N.

J Clin Endocrinol Metab. 2007 Dec;92(12):4845-52. Epub 2007 Sep 11.

PMID:
17848408
16.

Inhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis.

Poulaki V, Iliaki E, Mitsiades N, Mitsiades CS, Paulus YN, Bula DV, Gragoudas ES, Miller JW.

FASEB J. 2007 Jul;21(9):2113-23. Epub 2007 Mar 30.

PMID:
17400913
17.

Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.

Mitsiades CS, Negri J, McMullan C, McMillin DW, Sozopoulos E, Fanourakis G, Voutsinas G, Tseleni-Balafouta S, Poulaki V, Batt D, Mitsiades N.

Mol Cancer Ther. 2007 Mar;6(3):1070-8.

18.

VLA-4 blockade suppresses endotoxin-induced uveitis: in vivo evidence for functional integrin up-regulation.

Hafezi-Moghadam A, Noda K, Almulki L, Iliaki EF, Poulaki V, Thomas KL, Nakazawa T, Hisatomi T, Miller JW, Gragoudas ES.

FASEB J. 2007 Feb;21(2):464-74. Epub 2007 Jan 3.

PMID:
17202250
19.

Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.

Mitsiades CS, McMillin D, Kotoula V, Poulaki V, McMullan C, Negri J, Fanourakis G, Tseleni-Balafouta S, Ain KB, Mitsiades N.

J Clin Endocrinol Metab. 2006 Oct;91(10):4013-21. Epub 2006 Jul 18.

PMID:
16849420
20.

Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis.

Mitsiades CS, Kotoula V, Poulaki V, Sozopoulos E, Negri J, Charalambous E, Fanourakis G, Voutsinas G, Tseleni-Balafouta S, Mitsiades N.

J Clin Endocrinol Metab. 2006 Sep;91(9):3662-6. Epub 2006 Jul 5.

PMID:
16822827
21.

Overexpression of FasL in retinal pigment epithelial cells reduces choroidal neovascularization.

Semkova I, Fauser S, Lappas A, Smyth N, Kociok N, Kirchhof B, Paulsson M, Poulaki V, Joussen AM.

FASEB J. 2006 Aug;20(10):1689-91. Epub 2006 Jun 28.

PMID:
16807368
22.

Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation.

Mitsiades CS, Poulaki V, Fanourakis G, Sozopoulos E, McMillin D, Wen Z, Voutsinas G, Tseleni-Balafouta S, Mitsiades N.

Clin Cancer Res. 2006 Jun 15;12(12):3705-12.

23.

Geldanamycin treatment reduces neovascularization in a mouse model of retinopathy of prematurity.

Kociok N, Krohne TU, Poulaki V, Joussen AM.

Graefes Arch Clin Exp Ophthalmol. 2007 Feb;245(2):258-66.

PMID:
16741710
24.

Antimyeloma activity of heat shock protein-90 inhibition.

Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Kung AL, Davies FE, Morgan G, Akiyama M, Shringarpure R, Munshi NC, Richardson PG, Hideshima T, Chauhan D, Gu X, Bailey C, Joseph M, Libermann TA, Rosen NS, Anderson KC.

Blood. 2006 Feb 1;107(3):1092-100. Epub 2005 Oct 18.

25.

Novel histone deacetylase inhibitors in the treatment of thyroid cancer.

Mitsiades CS, Poulaki V, McMullan C, Negri J, Fanourakis G, Goudopoulou A, Richon VM, Marks PA, Mitsiades N.

Clin Cancer Res. 2005 May 15;11(10):3958-65.

26.

Human retinoblastoma cells are resistant to apoptosis induced by death receptors: role of caspase-8 gene silencing.

Poulaki V, Mitsiades CS, McMullan C, Fanourakis G, Negri J, Goudopoulou A, Halikias IX, Voutsinas G, Tseleni-Balafouta S, Miller JW, Mitsiades N.

Invest Ophthalmol Vis Sci. 2005 Jan;46(1):358-66.

PMID:
15623796
27.

Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy.

Poulaki V, Joussen AM, Mitsiades N, Mitsiades CS, Iliaki EF, Adamis AP.

Am J Pathol. 2004 Aug;165(2):457-69.

28.

A central role for inflammation in the pathogenesis of diabetic retinopathy.

Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraermeyer U, Kociok N, Fauser S, Kirchhof B, Kern TS, Adamis AP.

FASEB J. 2004 Sep;18(12):1450-2. Epub 2004 Jul 1.

PMID:
15231732
29.

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.

Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Libermann TA, García-Echeverría C, Pearson MA, Hofmann F, Anderson KC, Kung AL.

Cancer Cell. 2004 Mar;5(3):221-30.

30.

Activin a in the regulation of corneal neovascularization and vascular endothelial growth factor expression.

Poulaki V, Mitsiades N, Kruse FE, Radetzky S, Iliaki E, Kirchhof B, Joussen AM.

Am J Pathol. 2004 Apr;164(4):1293-302.

31.

VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2.

Usui T, Ishida S, Yamashiro K, Kaji Y, Poulaki V, Moore J, Moore T, Amano S, Horikawa Y, Dartt D, Golding M, Shima DT, Adamis AP.

Invest Ophthalmol Vis Sci. 2004 Feb;45(2):368-74.

PMID:
14744874
32.

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.

Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan D, Munshi N, Gu X, Bailey C, Joseph M, Libermann TA, Richon VM, Marks PA, Anderson KC.

Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):540-5. Epub 2003 Dec 26.

33.

Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas.

Poulaki V, Mitsiades CS, McMullan C, Sykoutri D, Fanourakis G, Kotoula V, Tseleni-Balafouta S, Koutras DA, Mitsiades N.

J Clin Endocrinol Metab. 2003 Nov;88(11):5392-8.

PMID:
14602779
34.

Effect of imatinib mesylate (Gleevec) on anaplastic thyroid carcinoma cell lines.

Mitsiades CS, Sykoutri D, McMullan C, Poulaki V, Mitsiades N.

J Clin Endocrinol Metab. 2003 Oct;88(10):5043-4; author reply 5044. No abstract available.

PMID:
14557495
35.

The role of advanced glycation end products in retinal microvascular leukostasis.

Moore TC, Moore JE, Kaji Y, Frizzell N, Usui T, Poulaki V, Campbell IL, Stitt AW, Gardiner TA, Archer DB, Adamis AP.

Invest Ophthalmol Vis Sci. 2003 Oct;44(10):4457-64.

PMID:
14507893
36.

Retinectomy for treatment of intractable glaucoma: long term results.

Joussen AM, Walter P, Jonescu-Cuypers CP, Koizumi K, Poulaki V, Bartz-Schmidt KU, Krieglstein GK, Kirchhof B.

Br J Ophthalmol. 2003 Sep;87(9):1094-102.

37.

The role of apoptosis-inducing receptors of the tumor necrosis factor family in thyroid cancer.

Mitsiades CS, Poulaki V, Mitsiades N.

J Endocrinol. 2003 Aug;178(2):205-16. Review.

PMID:
12904168
38.

Microdissection, microarrays and proteomics: a new approach to the study of eye diseases.

Poulaki V.

Graefes Arch Clin Exp Ophthalmol. 2003 Jul;241(7):527-528. doi: 10.1007/s00417-003-0713-x. Epub 2003 Jun 26. No abstract available.

PMID:
12836036
39.

Contribution of TNF-alpha to leukocyte adhesion, vascular leakage, and apoptotic cell death in endotoxin-induced uveitis in vivo.

Koizumi K, Poulaki V, Doehmen S, Welsandt G, Radetzky S, Lappas A, Kociok N, Kirchhof B, Joussen AM.

Invest Ophthalmol Vis Sci. 2003 May;44(5):2184-91. Erratum in: Invest Ophthalmol Vis Sci. 2016 Feb;57(2):403.

PMID:
12714660
40.

Molecular sequelae of histone deacetylase inhibition in human malignant B cells.

Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G, Schlossman R, Chauhan D, Munshi NC, Hideshima T, Richon VM, Marks PA, Anderson KC.

Blood. 2003 May 15;101(10):4055-62. Epub 2003 Jan 16.

41.

VEGF-dependent conjunctivalization of the corneal surface.

Joussen AM, Poulaki V, Mitsiades N, Stechschulte SU, Kirchhof B, Dartt DA, Fong GH, Rudge J, Wiegand SJ, Yancopoulos GD, Adamis AP.

Invest Ophthalmol Vis Sci. 2003 Jan;44(1):117-23.

PMID:
12506063
42.

Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes.

Joussen AM, Poulaki V, Mitsiades N, Cai WY, Suzuma I, Pak J, Ju ST, Rook SL, Esser P, Mitsiades CS, Kirchhof B, Adamis AP, Aiello LP.

FASEB J. 2003 Jan;17(1):76-8. Epub 2002 Nov 15.

PMID:
12475915
43.

Constitutive nuclear factor-kappaB activity is crucial for human retinoblastoma cell viability.

Poulaki V, Mitsiades CS, Joussen AM, Lappas A, Kirchhof B, Mitsiades N.

Am J Pathol. 2002 Dec;161(6):2229-40.

44.

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.

Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Schlossman R, Munshi NC, Hideshima T, Anderson KC.

Blood. 2003 Mar 15;101(6):2377-80. Epub 2002 Nov 7.

45.

Molecular sequelae of proteasome inhibition in human multiple myeloma cells.

Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, Munshi NC, Richardson PG, Hideshima T, Anderson KC.

Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14374-9. Epub 2002 Oct 21.

46.

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.

Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC.

Oncogene. 2002 Aug 22;21(37):5673-83.

47.

Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells.

Poulaki V, Mitsiades CS, Kotoula V, Tseleni-Balafouta S, Ashkenazi A, Koutras DA, Mitsiades N.

Am J Pathol. 2002 Aug;161(2):643-54.

48.

BMS-275291. Bristol-Myers Squibb.

Poulaki V.

Curr Opin Investig Drugs. 2002 Mar;3(3):500-4. Review.

PMID:
12054103
49.

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.

Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP, Anderson KC.

Blood. 2002 Jun 15;99(12):4525-30.

50.

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications.

Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi N, Treon SP, Anderson KC.

Blood. 2002 Jun 1;99(11):4079-86.

Supplemental Content

Loading ...
Support Center